Govita Tech is a venture-backed biotech company providing personalized solutions to predict and prevent chronic diseases, improve health, delay aging and enhance overall quality of life. Focus on mental wellbeing, thyroid functions, cardiovascular health, immunity, antioxidation, detoxification, hormone balance, muscle mass, joint health. Co-developed specially formulated detoxification and rejuvenation medical food, body composition ultrasound device with technology patent filed.

Business strategy is based on combination of models to accelerate the company’s growth; B2C VIP clients provided tests (280 biomarkers, 28 testing packages), assessment, personalized intervention, consultation; B2B – collaboration with clinics-healthcare providers, B2C&B direct sale of proprietary supplements and novel health monitoring devices. 2019 estimated revenue 15 million HKD to be increased to 30-40 million HKD in three years.

We developed unique DNA chips with the genes encoding metabolic enzymes, transporters and receptors in specific metabolic pathways; and metabolic panels. Selected metabolic levels will be used to trigger our proprietary algorithm to auto-generate personalized intervention formula for certain chronic disease conditions. IP with the trade mark GMDAI (genetic metabolic data associated intervention pending).

Govita developed 6 GMDAI approaches addressing 6 chronic conditions - depression, hypothyroidism, cardiovascular disease risks, fatigue, insomnia, urinary tract infections, sarcopenia, arthritis, with new ones under development. Excellent feedback >97% customer satisfaction from initial clients/clinics. We envision advancing promising collaborative programs successfully and expanding to EU and Israel

R&D

Continuous fine-tuning of the existing, new development of more multiomics panels and new medical food.

Creating partnership opportunities in conducting clinical studies on some of new intervention proprietary supplements and health monitoring devices.

Govita Tech is dedicated to providing innovative solutions to predict and prevent diseases and rejuvenate health. We plan to expand our organization and market development staff to EU and Israel. Our team of experts is poised to initiate new business models and achieve both great business results and valuable human gains

Planning to start B series funding in 2020 aimed at IPO. Open to merger with companies complementing and expanding our work in 3 years.